Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine.
暂无分享,去创建一个
E. Shin | Y. Lim | Young‐Woock Noh | S. Moon
[1] Y. Shoenfeld,et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. , 2013, Journal of autoimmunity.
[2] N. Petrovsky,et al. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. , 2013, Vaccine.
[3] N. Petrovsky,et al. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. , 2012, Vaccine.
[4] A. Musacchio,et al. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults , 2011, Human vaccines.
[5] A. Didierlaurent,et al. Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach , 2011, BioDrugs.
[6] Marc Lipsitch,et al. Vaccine production, distribution, access, and uptake , 2011, The Lancet.
[7] E. Montomoli,et al. Current adjuvants and new perspectives in vaccine formulation , 2011, Expert review of vaccines.
[8] N. Garçon,et al. The safety evaluation of adjuvants during vaccine development: the AS04 experience. , 2011, Vaccine.
[9] M. Tao,et al. Hydrogel-Delivered GM-CSF Overcomes Nonresponsiveness to Hepatitis B Vaccine through the Recruitment and Activation of Dendritic Cells , 2010, The Journal of Immunology.
[10] O. Leo,et al. Innate immunity and vaccine adjuvants: From concepts to the development of a unique adjuvant system as04 used for the formulation of a human papillomavirus (hpv) vaccine , 2010 .
[11] Arnaud M. Didierlaurent,et al. AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1 , 2009, The Journal of Immunology.
[12] Thomas Breuer,et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. , 2008, Vaccine.
[13] T. Mitchell,et al. Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant , 2008, Cellular and Molecular Life Sciences.
[14] Rino Rappuoli,et al. Bridging the knowledge gaps in vaccine design , 2007, Nature Biotechnology.
[15] B. Guy,et al. The perfect mix: recent progress in adjuvant research , 2007, Nature Reviews Microbiology.
[16] Brigitte Colau,et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.
[17] J. Brewer. (How) do aluminium adjuvants work? , 2006, Immunology letters.
[18] G. Dougan,et al. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. , 2005, Vaccine.
[19] Jeffrey B Ulmer,et al. Targeting the innate immune response with improved vaccine adjuvants , 2005, Nature Medicine.
[20] J. Paul Robinson,et al. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. , 2005, Vaccine.
[21] A. Iwasaki,et al. Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.
[22] N. Petrovsky,et al. Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.
[23] D. Persing,et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents , 2004, Expert opinion on biological therapy.
[24] J. Eldridge,et al. Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. , 2004, Vaccine.
[25] D. Lavanchy,et al. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.
[26] S. Michalek,et al. Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A , 2003, Infection and Immunity.
[27] D. Persing,et al. Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529 , 2003, Expert review of vaccines.
[28] Ruslan Medzhitov,et al. Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.
[29] H. HogenEsch,et al. Mechanisms of stimulation of the immune response by aluminum adjuvants. , 2002, Vaccine.
[30] P. van Damme,et al. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. , 2000, Vaccine.
[31] S. Romagnani. Th1/Th2 cells. , 1999, Inflammatory bowel diseases.
[32] A. Krieg,et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.
[33] M. Tomai,et al. T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin. , 1989, Journal of biological response modifiers.
[34] F. André. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. , 1989, The American journal of medicine.
[35] B. Yvonnet,et al. SEVEN-YEAR STUDY OF HEPATITIS B VACCINE EFFICACY IN INFANTS FROM AN ENDEMIC AREA (SENEGAL) , 1986, The Lancet.
[36] S. Hadler,et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. , 1986, The New England journal of medicine.
[37] G. Keating,et al. Recombinant Hepatitis B Vaccine (Engerix-B®) , 2012, Drugs.
[38] R. Gupta,et al. The role of adjuvants and delivery systems in modulation of immune response to vaccines. , 1996, Advances in experimental medicine and biology.